ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ペントキシフィリン

Pentoxifylline

HCID 4740
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
6493-05-6
標準SMILES
CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O
InChIKey
BYPFEZZEUUWMEJ-UHFFFAOYSA-N
分子式
C13H18N4O3
平均分子量
278.31 g/mol
単同位体質量
278.13789045

概要

Pentoxifylline is an oxopurine.

名称と識別子

優先名称
Pentoxifylline
IUPAC
3,7-dimethyl-1-(5-oxohexyl)purine-2,6-dione
現地名
ペントキシフィリン
英語名
Pentoxifylline
分子式
C13H18N4O3
分子量
278.31

名称と別名

pentoxifylline6493-05-6TrentalOxpentifyllinePentoxilPentoxyphyllinePentoxiphyllin1-(5-Oxohexyl)theobrominePentoxifilina3,7-Dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dioneBL 1911H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)-
名称をさらに表示
1-(5-オキソヘキシル)-3,7-ジメチル-1,2,3,6-テトラヒドロ-7H-プリン-2,6-ジオンオクスペンチフィリン3,7-ジヒドロ-3,7-ジメチル-1-(5-オキソヘキシル)-1H-プリン-2,6-ジオントレンタールペントキシフィリン1-(5-オキソヘキシル)-3,7-ジメチルキサンチン1-(5-オキソヘキシル)-3,7-ジヒドロ-3,7-ジメチル-1H-プリン-2,6-ジオン1-(5-オキソヘキシル)テオブロミン3,7-ジメチル-1-(5-オキソヘキシル)キサンチンペントキシフィリン標準品ペントキシフィリン (JAN)3,7-ジメチル-1-(5-オキソヘキシル)-2,3,6,7-テトラヒドロ-1H-プリン-2,6-ジオンPTXPENTOXYFYLLINE3,7-Dimethyl3,7-Dimethyl-1-(5-oxohexyl)-3,7-dihydro-1H-purine-2,6-dionePENTOXIFYLINEPentoxyfillinePENTOXYIFYLLINEbl191
BL-191OxypentifyllinePentoxifyllinumDTXSID7023437SD6QCT3TSUNSC637086NSC-637086NSC-758481

データベース識別子

CAS
6493-05-6
PubChem CID
4740
DTXSID
DTXSID7023437
ChEMBL
CHEMBL628
ChEBI
CHEBI:7986
UNII
SD6QCT3TSU
EC Number
229-374-5
Nikkaji
J3.419C

物性

構造計算による物性

XLogP
0.3
極性表面積
75.5 Ų
水素結合供与体数
0
水素結合受容体数
4
回転可能結合数
5
重原子数
20
形式電荷
0
複雑度
426

実験および物理化学的性質

Chemical ClassesPharmaceutical
Drugs · 4 件

Pharmaceuticals -> Listed in ZINC15

Pharmaceutical

Pharmaceuticals

Pharmaceuticals -> Used in Switzerland

LogP0.29
Solubility5.17e+00 g/L
Human Drugs · 4 件

Breast Feeding; Lactation; Hematologic Agents; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors; Xanthines

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Melting Point105 °C
Physical DescriptionSolid
Ionization Efficiency · 6 件

Positive

2.07

2.7

Agilent XCT

Electrospray ionization

formic acid (5.3nM)

Collision Cross Section · 3 件

172.0 Ų [M+Na]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: TOXCAST; Source Identifier: DTXSID7023437]

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 5 件

This chemical does not meet GHS hazard criteria for 4.5% (3 of 67) of reports.

Warning

H302 (95.5%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 67 reports by companies from 5 notifications to the ECHA C&L Inventory.

危険有害性情報

Other Safety InformationIMAP assessments - 1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)-: Human health tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (95.5%)

毒性情報

Hepatotoxicity · 1 件

Chronic therapy with pentoxifylline has not been associated with elevations in serum enzyme levels, although the rigor with which liver test abnormalities were sought in patients taking the drug was not always clear. Despite its use for more than 3 decades, pentoxifylline has been linked to only rare and not completely convincing cases of clinically apparent liver injury. Nevertheless, adverse effects of hepatitis, jaundice, cholestasis and increased liver enzymes are listed in product labels for pentoxifylline. In reported cases, the time to onset was 3 to 4 weeks and the pattern of liver enzyme elevations was distinctly cholestatic (Case 1). Autoimmune and immunoallergic features were not present. The injury was self-limited and there have been no reports of acute liver failure, chronic hepatitis or vanishing bile duct syndrome associated with pentoxifylline therapy.

Adverse EffectsThe most common adverse effect of pentoxifylline is nausea and vomiting. Other common adverse drug reactions are listed below.

化学と産業

薬理情報

ATC Code · 3 件

C04AD03

C - Cardiovascular system

QC - Cardiovascular system

Protein BindingPentoxifylline is approximately 45% bound to erythrocyte membranes.
Pharmacodynamics · 1 件

Pentoxifylline, a synthetic dimethylxanthine derivative structurally related to [theophylline] and [caffeine], exhibits hemorheological, anti-oxidative, and anti-inflammatory properties and is traditionally indicated in the treatment of peripheral arterial disease (PAD). In PAD patients with concurrent cerebrovascular and coronary artery diseases, pentoxifylline treatment has occasionally been associated with angina, arrhythmia, and hypotension. Concurrent use with [warfarin] should be associated with more frequent monitoring of prothrombin times. Also, patients with risk factors complicated by hemorrhages, such as retinal bleeding, peptic ulceration, and recent surgery, should be monitored periodically for bleeding signs.

Mechanism of Action · 1 件

Patients with peripheral arterial disease (PAD) may suffer from intermittent claudication, exertional leg pain that resolves upon rest, which is underscored by a complex etiology including vascular dysfunction (reduced limb perfusion, angiogenesis, and microcirculatory flow), systemic inflammation, and skeletal muscle dysfunction. Pentoxifylline (PTX), (3,7-dimethyl-1-(5-oxohexyl)-3,7-dihydro-1H-purine-2,6-dione) or 1-(5-oxohexyl)-3,7-­dimethylxanthine, is a methyl-xanthine derivative that acts to lower blood viscosity by increasing erythrocyte flexibility, reducing plasma fibrinogen, inhibiting neutrophil activation, and suppressing erythrocyte/platelet aggregation; it also has antioxidant and anti-inflammatory effects. Although the precise mechanism of action has yet to be elucidated, numerous studies have suggested several effects of PTX. The classical interpretation of PTX's broad effects is due to its ability to act, _in vitro_, as a non-specific cyclic-3',5'-phosphodiesterase (PDE) inhibitor at millimolar concentrations; specifically, it has been proposed that inhibition of PDE type III and IV isozymes leads to elevated cyclic adenosine monophosphate (cAMP) levels, which mediate diverse downstream effects. This view has been challenged, specifically by observing those plasma concentrations of PTX in routine clinical use are typically only around 1μM, far lower than those used to inhibit PDEs _in vitro_. Instead, several studies have suggested that PTX can modulate adenosine receptor function, specifically the Gα-coupled A2A receptor (A2AR). Whether PTX acts directly as an A2AR agonist is unclear, although it can clearly increase the response of A2AR to adenosine. A2AR activation activates adenylyl cyclase, which increases intracellular cAMP levels; this observation may explain PTX's ability to increase intracellular cAMP in a PDE-independent fashion. Elevated cAMP levels have numerous downstream effects. cAMP-mediated activation of protein kinase A (PKA) suppresses nuclear translocation of NF-κB, which suppresses transcription of pro-inflammatory cytokines such as tumour necrosis factor (TNF-α), interleukin-1 (IL-1), and IL-6 as well as TNF-induced molecules such as adhesion molecules (ICAM1 and VCAM1) and the C-reactive protein (CRP). PTX has also been shown to prevent the downstream phosphorylation of p38 MAPK and ERK, which are responsible for assembling the NADPH oxidase involved in the neutrophil oxidative burst. This effect is due to a PKA-independent decrease in Akt phosphorylation and a PKA-dependent decrease in phosphorylation of p38 MAPK and ERK. This transcriptional regulation at least partially explains the anti-inflammatory and anti-oxidative properties of PTX. Also, activated PKA can activate the cAMP response element-binding protein (CREB), which itself blocks SMAD-driven gene transcription, effectively disrupting transforming growth factor (TGF-β1) signalling. This results in lower levels of fibrinogenic molecules such as collagens, fibronectin, connective tissue growth factor, and alpha-smooth muscle actin. Hence, disruption of TGF-β1 signalling may explain the anti-fibrotic effects of PTX, including at least some of the decrease in blood viscosity. The picture is complicated by the observation that PTX metabolites M1, M4, and M5 have been shown to inhibit C5 Des Arg- and formyl-methionylleucylphenylalanine-induced superoxide production in neutrophils and M1 and M5 significantly contribute to PTX's observed hemorheological effects. Overall, PTX administration is associated with decreased pro-inflammatory molecules, an increase in anti-inflammatory molecules such as IL-10, and decreased production of fibrinogenic and cellular adhesion molecules.

関連反応

8 件
反応記録を作成
HRID 1762546 の反応式
HRID 1762546反応物として
HRID 1762552 の反応式
HRID 1762552反応物として
HRID 2200759 の反応式
HRID 2200759反応物として
HRID 2418876 の反応式
HRID 2418876反応物として
HRID 2418886 の反応式
HRID 2418886反応物として
HRID 2418891 の反応式
HRID 2418891反応物として
HRID 2418899 の反応式
HRID 2418899反応物として
HRID 2418910 の反応式
HRID 2418910反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

158.5 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

167.95 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

融点
98 · 98-100°C
沸点
421.13 °C · 421.13°C (rough estimate)
比重(密度)
1.1713 · 1.1713 (rough estimate)
屈折率
1.6 · 1.6000 (estimate)
貯蔵温度
Sealed in dry,Room Temperature
溶解性
2 O: · H2O: ≥43 mg/mL
外見
個体
酸解離定数(Pka)
0.5 · 0.50±0.70(Predicted)
色
白い
水溶解度
2 O: · H2O: ≥43mg/mL, colorless to almost colorless
Merck
14 · 14,7136
主な用途
医薬品(低分子化合物)
InChI
1S/C13H20N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8,10-11H,4-7H2,1-3H3
InChIKey
MQGNNJQTNFHNHK-UHFFFAOYSA-N
SMILES
CN1C=NC2C1C(=O)N(CCCCC(C)=O)C(=O)N2C
CAS データベース
6493 · 6493-05-6(CAS DataBase Reference)
NISTの化学物質情報
Pentoxifylline(6493-05-6)
EPAの化学物質情報
1 H-Purine-2,6-dione, · 1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)- (6493-05-6)

化学的性質

化学的特性White to Off-White Solid

Toxicity Summary
Signs and Symptoms of Overdose
Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Pentoxifylline

Ambiguous-DILI-concern

5

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
USGS Health-Based Screening Levels for Evaluating Water-Quality · 3 件

Pentoxifylline

Pharmaceutical

Smith, C.D. and Nowell, L.H., 2024. Health-Based Screening Levels for evaluating water-quality data (3rd ed.). DOI:10.5066/F71C1TWP

EPA Human Health Benchmarks for Pharmaceuticals · 6 件

Pentoxifylline

28.0

118.3

The usual dosage of pentoxifylline in extended-release tablet form is one tablet (400 mg) three times a day with meals.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 1200 mg/day, Lowest Therapeutic Dose (LTD): 15.0 mg/kg-day, and Screening Dose: 0.005 mg/kg-day.

19-Nov-19

安全データ

wgk
3
rtecs
XH2475000
毒性
LD50 orally in mice: 1385 mg/kg (Popendiker)
hs_code
2939590000
risk_code
22
hazard_code
Xn
safety_code
36
Hazard Classifications
Acute Tox. 4 OralLact.
ストレージクラス
11 - Combustible Solids
Biological Half-LifeOverall, pentoxifylline has an elimination half-life of between 0.39 and 0.84 hours, while its primary metabolites have elimination half-lives of between 0.96 and 1.61 hours.
Metabolism/Metabolites · 2 件

Pentoxifylline (PTX) metabolism is incompletely understood. There are seven known metabolites (M1 through M7), although only M1, M4, and M5 are detected in plasma at appreciable levels, following the general pattern M5 > M1 > PTX > M4. As PTX apparent clearance is higher than hepatic blood flow and the AUC ratio of M1 to PTX is not appreciably different in cirrhotic patients, it is clear that erythrocytes are the main site of PTX-M1 interconversion. However, the reaction likely occurs in the liver as well. PTX is reduced in an NADPH-dependent manner by unknown an unidentified carbonyl reductase to form either [lisofylline] (the (R)-M1 enantiomer) or (S)-M1; the reaction is stereoselective, producing (S)-M1 exclusively in liver cytosol, 85% (S)-M1 in liver microsomes, and a ratio of 0.010-0.025 R:S-M1 after IV or oral dosing in humans. Although both (R)- and (S)-M1 can be oxidized back into PTX, (R)-M1 can also give rise to M2 and M3 in liver microsomes. _In vitro_ studies suggest that CYP1A2 is at least partly responsible for the conversion of [lisofylline] ((R)-M1) back into PTX. Unlike the reversible oxidation/reduction of PTX and its M1 metabolites, M4 and M5 are formed via irreversible oxidation of PTX in the liver. Studies in mice recapitulating the PTX-ciprofloxacin drug reaction suggest that CYP1A2 is responsible for the formation of M6 from PTX and of M7 from M1, both through de-methylation at position 7. In general, metabolites M2, M3, and M6 are formed at very low levels in mammals.

Pentoxifylline is a known human metabolite of lisofylline.

FDA Pharmacological Classification · 6 件

SD6QCT3TSU

PENTOXIFYLLINE

Established Pharmacologic Class [EPC] - Blood Viscosity Reducer

Physiologic Effects [PE] - Hematologic Activity Alteration

Pentoxifylline is a Blood Viscosity Reducer. The physiologic effect of pentoxifylline is by means of Hematologic Activity Alteration.

PENTOXIFYLLINE

MeSH Pharmacological Classification · 5 件

Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases.

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.

Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other purposes, e.g. military.

Drugs used to cause dilation of the blood vessels.

Substances that eliminate free radicals. Among other effects, they protect PANCREATIC ISLETS against damage by CYTOKINES and prevent myocardial and pulmonary REPERFUSION INJURY.

Absorption, Distribution and Excretion · 4 件

Oral pentoxifylline (PTX) is almost completely absorbed but has low bioavailability of 20-30% due to extensive first-pass metabolism; three of the seven known metabolites, M1, M4, and M5 are present in plasma and appear soon after dosing. Single oral doses of 100, 200, and 400 mg of pentoxifylline in healthy males produced a mean tmax of 0.29-0.41 h, a mean Cmax of 272-1607 ng/mL, and a mean AUC0-∞ of 193-1229 ng\*h/mL; corresponding ranges for metabolites 1, 4, and 5 were 0.72-1.15, 114-2753, and 189-7057. Single administration of a 400 mg extended-release tablet resulted in a heightened tmax of 2.08 ± 1.16 h, lowered Cmax of 55.33 ± 22.04 ng/mL, and a comparable AUC0-t of 516 ± 165 ng\*h/mL; all these parameters were increased in cirrhotic patients. Smoking was associated with a decrease in the Cmax and AUCsteady-state of metabolite M1 but did not dramatically affect the pharmacokinetic parameters of pentoxifylline or other measured metabolites. Renal impairment increases the mean Cmax, AUC, and ratio to parent compound AUC of metabolites M4 and M5, but has no significant effect on PTX or M1 pharmacokinetics. Finally, similar to cirrhotic patients, the Cmax and tmax of PTX and its metabolites are increased in patients with varying degrees of chronic heart failure. Overall, metabolites M1 and M5 exhibit plasma concentrations roughly five and eight times greater than PTX, respectively. PTX and M1 pharmacokinetics are approximately dose-dependent, while those of M5 are not. Food intake before PTX ingestion delays time to peak plasma concentrations but not overall absorption. Extended-release forms of PTX extend the tmax to between two and four hours but also serves to ameliorate peaks and troughs in plasma concentration over time.

Pentoxifylline is eliminated almost entirely in the urine and predominantly as M5, which accounts for between 57 and 65 percent of the administered dose. Smaller amounts of M4 are recovered, while M1 and the parent compound account for less than 1% of the recovered dose. The fecal route accounts for less than 4% of the administered dose.

Pentoxifylline has a volume of distribution of 4.15 ± 0.85 following a single intravenous 100 mg dose in healthy subjects.

Pentoxifylline given as a single 100 mg intravenous infusion has a clearance of 3.62 ± 0.75 L/h/kg in healthy subjects, which decreased to 1.44 ± 0.46 L/h/kg in cirrhotic patients. In another study, the apparent clearance of either 300 or 600 mg of pentoxifylline given intravenously (median and range) was 4.2 (2.8-6.3) and 4.1 (2.3-4.6) L/min, respectively. It is important to note that, due to the reversible extra-hepatic metabolism of the parent compound and metabolite 1, the true clearance of pentoxifylline may be even higher than the measured values.

Cellular LocationsCytoplasm

用途と製造

UsesUse (kg; approx.) in Germany (2009): >25000
Use ClassificationPharmaceuticals
応用分野 · 1 件

使用Pentoxifylline is a methylxanthine phospho-diesterase inhibitor with favorable antiinflammatory effects and immunoregulatory properties.A metabolite of Pentifylline. Methylxanthine derivative that improves blood flow by decreasing blood viscosity. Phosphodiesterase inhibitor. Inhibits the synthesis of tumor necrosis factor a (TNF-a).

上流・下流製品情報

上流原料

アセト酢酸エチルDihydropyranテオブロミン1-ブロモ-3-クロロプロパン6-ブロモ-2-ヘキサノン